The global autosomal dominant polycystic kidney disease treatmentmarket is anticipated to attain a valuation of US$ 1,197.3 million in2023 and is projected to reach US$ 2,140 million by 2033, trailing at a CAGR of 5.97% during the forecast period.
The polycystic kidney disease market is propelled by surging incidences of renal failure or dialysis. This disease can be caused by a number of factors, including a family history of kidney problems, a rare genetic mutation, kidney failure, or people undergoing dialysis, which boosts the market growth.
Another crucial factor driving the growth of polycystic kidney disease market is the increasing healthcare expenditure which helps in enhancing its infrastructure. Moreover, growing initiatives by public and private organizations to spread awareness is expected to expand the polycystic kidney disease treatment market. High disposable income and surging demand for advanced treatment and innovative solutions will result in the growth of polycystic kidney disease treatment industry. Also, favourable government policies and growing awareness about genetic diseases among people will positively benefit the growth of this market.
Report Attributes
Details
Expected Market Value (2023)
US$ 1,197.3 million
Anticipated Forecast Value (2033)
US$ 2,140 million
Projected Growth Rate (2023 to 2033)
CAGR 5.97%
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
2018 to 2022 Autosomal dominant polycystic kidney disease treatment Demand Analysis vs. Forecast 2023 to 2033
The industry for Autosomal dominant polycystic kidney disease treatment recorded a valuation of US$ 954 million in 2018, while growing at a CAGR of 4.65% during the historical period. The market's growth is driven by rising number of research and development activities. This will provide lucrative opportunities for growth of polycystic kidney disease treatment market. Also, increasing drug approvals and launches will further fuel the market’s growth rate.
On the other hand, increasing investments for the development of advanced technologies and growth in the number of emerging markets will further provide lucrative opportunities for the polycystic kidney disease market growth during the projected period.Likewise, Leading ADPKD companies like, Galapagos NV, Anakuria Therapeutics, Reata Pharmaceuticals, Kadmon Pharmaceuticals, Sanofi, Regulus Therapeutics, AceLink Therapeutics, Healx, XORTX Therapeutics, Poxel, Alebund Pharmaceuticals, Chinook Therapeutics, and few others are developing novel Autosomal dominant polycystic kidney disease drugs that can be available in the market in the forthcoming years which will benefit the industry’s growth.
‘JYNARQUE’ is a novel drug in the form of pill which is taken twice a day that delays the growth of cysts and has been shown to regulate kidney function. It is a long-term use drug, thus extending the timeframe before a person requires dialysis or a kidney transplant, though it doesn’t cure polycystic kidney disease. This drug was developed by Otsuka Pharmaceuticals. Thus, arrival of similar kind of drugs will present growth opportunities for the market’s growth. After a comprehensive analysis of above-mentioned factors and developments, the revenue growth of Autosomal dominant polycystic kidney disease treatment market is projected to be worth US$ 2,140 million by end of the forecast period, while exhibiting a CAGR of 5.97%.
Which are Some Prominent Drivers spearheading the Autosomal dominant polycystic kidney disease treatment market?
Strong drug pipeline bolstering the industry growth
The adoption of promising Autosomal Dominant Polycystic Kidney Disease Treatment therapies in the pipeline like GLPG2737, Bardoxolone methyl, Tesevatinib, Venglustat, AT 20494, RGLS 8429, AL 01211, XRx-008, PXL770, and few others is expected to propel the growth of this market. Furthermore, the market size is anticipated to grow owing to expected launch of potential therapies and a rise in the diagnosed prevalent population of polycystic kidney disease around the world. Likewise, tolvaptan (Jynarque/Jinarc/Samsca) is the only approved drug developed by Otsuka Pharmaceuticals' in the world for the treatment of adults suffering from autosomal dominant polycystic kidney disease. This is anticipated to support market growth during the forecast period.
On the other hand, technological advancements in diagnostic procedures, as a result of a greater stress on early stage diagnosis, have condensed undiagnosed cases. Therefore, continuously increasing cases of diagnosed autosomal dominant polycystic kidney disease is providing opportunities for companies to launch new therapies in the concerned market. Also, advances are being made in determining the genetic causes of polycystic kidney disease, non-invasive monitoring, and in foreseeing disease progression, all of which will aid in management of disease and will help the market grow. In addition, pre-symptomatic diagnosis and its application in the care and management of Autosomal dominant polycystic kidney disease patients also contribute to the expansion of this market during the forecast period.
The polycystic kidney disease drug pipeline is strong and dynamic, with many products being created across different stages for autosomal dominant polycystic kidney disease, thereby driving the growth of autosomal dominant polycystic kidney disease treatment market. Furthermore, the discovery of biomarkers for early detection of polycystic patients at high risk of progression will aid in better managing polycystic disease patients and preventing disease progression.
Find your sweet spots for generating winning opportunities in this market.
What are the challenges expected to be Faced by the Market?
Discontinuation of treatment to restrain market expansion
The discontinuation of treatment due to inability to tolerate aquaretic agents, hepatic adversative events (abnormal liver function tests), progression of disease, and chronic kidney injury.
Also, dearth of awareness and limited knowledge of polycystic kidney disease among the patients and primary care physicians are noteworthy shortcomings in this market, that are most likely to hamper market’s growth.
Region-Wise Insights
What are the growth prospects in North America?
North America to dominate the market with maximum share
North America is expected to dominate the polycystic kidney disease market by accumulating market share of 39.5% by end of the forecast period. The growth is attributed to technological advancements and increasing number of government initiatives taken by pharmaceutical organizations to generate novel formulation in this region.
Rising inclination of patients towards early-stage diagnosis and treatment, favorable reimbursement policies and strong geographical presence of the leading players in the region is also anticipated to fuel growth of the polycystic kidney disease treatment market during the projected period. On the other hand, advancements in diagnosis and tests, increasing per capita income, and easy availability of drugs are expected to propel the polycystic kidney disease therapeutics market in the region.
What is the growth outlook in East Asia?
East Asia driving growth with fastest CAGR
The market in East Asia is anticipated to grow with fastest CAGR of 6.2% during the forecast period. This region is expected to be third largest market for polycystic kidney disease treatment by 2033. The regional growth is attributable to due to surging number of government initiatives for spreading awareness and presence of generic manufacturers. Also, growing awareness and increasing number of patient suffering from kidney diseases is leading to market expansion in this region.
Also, accessibility of technologically advanced products, and the presence of newly-incepted state-of-the-art healthcare facilities is leading to expansion of regional market. Increasing geriatric population, lifestyle stress, a huge population base, improved quality of diagnosis, and surging patient affordability are also aiding in market expansion.
Recently, China has proven to be an promising market for medical devices. In March 2019, the Chinese government decreased the Value Added Tax for medical manufacturing companies from 13.30% to 13.%. This is most likely to benefit domestic manufacturers of medical equipment’s, which will lead to growth of autosomal dominant polycystic kidney disease treatment market in East Asia.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Category wise Insights
By treatment type, which segment will possess market hegemony?
Pain and Inflammation segment to witness highest demand
This segment is expected to accumulate highest market share of 37.4% by end of the forecast period. Pain and inflammation treatment type segment is anticipated to experience highest demand since it is the first line therapy for the treatment of autosomal dominant polycystic kidney disease. For severe pain, non-opioid analgesics and conventional interventions are used first, before considering opioid analgesics. If pain still continues use of surgical interventions like renal cyst decortication, renal denervation and nephrectomy that can target pain induced by renal or hepatic cysts is advised by healthcare professionals which is expected to support segment’s growth.
There are effective surgical procedures that could be performed when more conservative treatments fail. Laparoscopic cyst decortication has been well studied and results in relieving chronic renal pain in the majority of patients which will aid in segment’s growth during the forecast period. Furthermore, renal denervation has been used successfully and can be performed alongside with cyst decortication. Nephrectomy should be kept limited for patients with intractable pain and renal failure when other modalities have failed.
By End User, which segment is expected to dominate the market?
Hospitals driving growth with significant market share
Hospitals segment is anticipated to contribute to highest revenue share of around 54% by end of the forecast period. The growth is attributable to high patient pool, robust healthcare infrastructure, easy accessibility of advanced machinery for dialysis and kidney stones, high availability of skilled healthcare professionals.
Furthermore, the first line therapies that are suggested by urologists and other healthcare specialists are generally available in hospital environments. Thus, it is expected to drive the segment’s growth during the forecast period.
Start-ups in Autosomal dominant polycystic kidney disease treatment market
Start-ups help in determining the future growth opportunities in any market. These new entrants have the potential to generate high returns which directly benefits the expansion of any industry. These start-ups are typically more efficient at transforming inputs into outputs with more flexibility and adaptability in nature, able to shift quickly in response to sensitive market conditions. Some of the start-ups that will bolster the expansion of Autosomal dominant polycystic kidney disease treatment market are:
Palladio Biosciences is a Newtown Square, United States-based start-up that was founded in 2016. This start-up is developing medicines for orphan diseases of kidney including Polycystic kidney disease. The company’s lead product is lixivaptan, a selective vasopressin V2 receptor antagonist currently in development for the treatment of polycystic kidney disease (Phase 2). It received funding of US$ 28 million from Samsara Bio Capital, Osage University Partners, and 2 others.
Founded in 2007, Regulus Therapeutics is a San Diego, United States based company that is focused on the discovery and development of microRNA therapeutics. This company is developing RG-101, an anti-miR for the treating Hepatitis C and RG-012, an anti-miR for treating Alport syndrome, a life-threatening genetic kidney disease. It is also advancing in various programs toward clinical development in oncology, fibrosis and metabolic diseases, both independently and with alliance partners. Each anti-miR is designed to bind with and inhibit a specific microRNA target that is up-regulated in a cell and that is included in the disease state. This start-up was granted funding of USD 35 million from New Enterprise Associates and Federated Hermes.
Founded in 2010, Primrose Therapeutics is a New York, United States-based biotechnology company focused on the development of treatments for Polycystic Kidney Disease (PKD). The average life expectancy of these patients is 64 years – at least a decade lesser than average. No Food and drug administration approved therapies presently exist for this devastating disease. This company was bought by stemline therapeutics in Sep 2011. It gathered total funding of USD 753 K.
Market Competition
The autosomal dominant polycystic kidney disease treatment market is intesely competitive and consists of several industry players. These players are developing novel delivery systems for treating Autosomal dominant polycystic kidney disease treatment. This is estimated to propel Autosomal dominant polycystic kidney disease treatment market. The key players in this industry are: Otsuka Pharmaceutical, Sanofi, Reata Pharmaceuticals, Galapagos NV, Janssen Pharmaceuticals, Regulus Therapeutics, Xortx Therapeutics, AceLink Therapeutics, Inc, PanoTherapeutics, Inc, and Exelixis, Inc.
To stay in the forefront of highly competitive market, the key market players are focusing on expanding their geographical reach and investing in product development. The practice of adopting organic as well as inorganic strategies by the players help the polycystic kidney disease treatment market to grow at a significant growth rate. This is anticipated to fuel the global Autosomal dominant polycystic kidney disease treatment market.
In July 2022, Grupo Olmos which is a provider of renal care solutions, declared that the company had acquired renal care business of Diaverum, a renal healthcare provider, that operates in Argentina. This acquisition will strengthen the renal product portfolio of the company.
In 2020, Palladio Biosciences declared about the first patient of autosomal dominant polycystic kidney disease dosed with lixivaptan which is a novel vasopressin V2 antagonist. They assured the safety of lixivaptan in these patients who earlier discontinued therapy with tolvaptan due to liver toxicity.
In March 2019, Aster Hospitals, the biggest private healthcare service providers operating in multiple GCC states, declared that it had launched an awareness and screening initiative to promote the prevention of chronic kidney disease through education, awareness, and early diagnosis.
In August 2022, Bayer announced launch of finerenone drug to treat chronic kidney disease associated with type-2 diabetes in India.
In July 2022, Health Canada accepted GlaxoSmithKline's new drug submission for daprodustat which is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for the treatment of patients with anemia of chronic kidney disease
Report Scope
Report Attributes
Details
Market Value in 2023
US$ 1,197.3 million
Market Value in 2033
US$ 2,140 million
Growth Rate
CAGR of 5.97% from 2023 to 2033
Base Year for Estimation
2022
Historical Data
2018 to 2022
Forecast Period
2023 to 2033
Quantitative Units
Revenue in US$ million and CAGR from 2023 to 2033
Report Coverage
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered
Treatment Type
End User
Region
Regions Covered
North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East and Africa
Key Countries Profiled
USA
Canada
Brazil
Mexico
Germany
UK
France
Spain
Italy
India
China
Japan
Indonesia
Singapore
Thailand
South Korea
Australia
New Zealand
GCC Countries
South Africa
Israel
Key Companies Profiled
Otsuka Pharmaceutical
Sanofi S.A
Reata Pharmaceuticals
Galapagos N.V
Janssen Pharmaceuticals
Regulus Therapeutics
Xortx Therapeutics
AceLink Therapeutics Inc.
Pano Therapeutics, Inc.
Exelixis, Inc.
Customization
Available Upon Request
Key Segments Profiled in the Autosomal Dominant Polycystic Kidney Disease Treatment Industry Survey
By Treatment Type:
Pain & Inflammation Treatment
Kidney Stone Treatment
Urinary Tract Infection Treatment
Kidney Failure Treatment
By End User:
Hospitals
Clinics
Ambulatory Surgical Centers
By Region:
North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East and Africa
Frequently Asked Questions
How big is the Autosomal Dominant Polycystic Kidney Disease Treatment Market?
The autosomal dominant polycystic kidney disease treatment market is worth US$ 1,197.3 million in 2023.
How big will the be market by 2033?
The autosomal dominant polycystic kidney disease treatment market is anticipated to be worth US$ 2,140 million by 2033.
What is the Autosomal Dominant Polycystic Kidney Disease Treatment Market’s CAGR?
The autosomal dominant polycystic kidney disease treatment market will thrive at 5.97% CAGR through 2033.
Which is the leading treatment type in the Autosomal Dominant Polycystic Kidney Disease Treatment Market?
The pain and inflammation segment will acquire 37.4% of the autosomal dominant polycystic kidney disease treatment market share by 2033.
Which region is swiftly expanding in the Autosomal Dominant Polycystic Kidney Disease Treatment Market?
The East Asia autosomal dominant polycystic kidney disease treatment market is predicted to thrive at a 6.2% CAGR through 2033.
Table of Content
1. Executive Summary | Autosomal Dominant Polycystic Kidney Disease Treatment Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Treatment Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment Type, 2023 to 2033
5.3.1. Pain & Inflammation Treatment
5.3.2. Kidney Stone Treatment
5.3.3. Urinary Tract Infection Treatment
5.3.4. Kidney Failure Treatment
5.4. Y-o-Y Growth Trend Analysis By Treatment Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Treatment Type, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End-User
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By End-User, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End-User, 2023 to 2033
6.3.1. Hospitals
6.3.2. Clinics
6.3.3. Ambulatory Surgical Centres
6.4. Y-o-Y Growth Trend Analysis By End-User, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By End-User, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. South Asia
7.3.5. East Asia
7.3.6. Oceania
7.3.7. Middle East and Africa
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. The USA
8.2.1.2. Canada
8.2.2. By Treatment Type
8.2.3. By End-User
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Treatment Type
8.3.3. By End-User
8.4. Key Takeaways
9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Treatment Type
9.2.3. By End-User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Treatment Type
9.3.3. By End-User
9.4. Key Takeaways
10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. United Kingdom (UK)
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Europe
10.2.2. By Treatment Type
10.2.3. By End-User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Treatment Type
10.3.3. By End-User
10.4. Key Takeaways
11. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. India
11.2.1.2. Malaysia
11.2.1.3. Singapore
11.2.1.4. Thailand
11.2.1.5. Rest of South Asia
11.2.2. By Treatment Type
11.2.3. By End-User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Treatment Type
11.3.3. By End-User
11.4. Key Takeaways
12. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. South Korea
12.2.2. By Treatment Type
12.2.3. By End-User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Treatment Type
12.3.3. By End-User
12.4. Key Takeaways
13. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. Australia
13.2.1.2. New Zealand
13.2.2. By Treatment Type
13.2.3. By End-User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Treatment Type
13.3.3. By End-User
13.4. Key Takeaways
14. MIDDLE EAST AND AFRICA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. South Africa
14.2.1.3. Israel
14.2.1.4. Rest of MIDDLE EAST AND AFRICA
14.2.2. By Treatment Type
14.2.3. By End-User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Treatment Type
14.3.3. By End-User
14.4. Key Takeaways
15. Key Countries Market Analysis
15.1. USA
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2022
15.1.2.1. By Treatment Type
15.1.2.2. By End-User
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2022
15.2.2.1. By Treatment Type
15.2.2.2. By End-User
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2022
15.3.2.1. By Treatment Type
15.3.2.2. By End-User
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2022
15.4.2.1. By Treatment Type
15.4.2.2. By End-User
15.5. Germany
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2022
15.5.2.1. By Treatment Type
15.5.2.2. By End-User
15.6. UK
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2022
15.6.2.1. By Treatment Type
15.6.2.2. By End-User
15.7. France
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2022
15.7.2.1. By Treatment Type
15.7.2.2. By End-User
15.8. Spain
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2022
15.8.2.1. By Treatment Type
15.8.2.2. By End-User
15.9. Italy
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2022
15.9.2.1. By Treatment Type
15.9.2.2. By End-User
15.10. India
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2022
15.10.2.1. By Treatment Type
15.10.2.2. By End-User
15.11. Malaysia
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2022
15.11.2.1. By Treatment Type
15.11.2.2. By End-User
15.12. Singapore
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2022
15.12.2.1. By Treatment Type
15.12.2.2. By End-User
15.13. Thailand
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2022
15.13.2.1. By Treatment Type
15.13.2.2. By End-User
15.14. China
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2022
15.14.2.1. By Treatment Type
15.14.2.2. By End-User
15.15. Japan
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2022
15.15.2.1. By Treatment Type
15.15.2.2. By End-User
15.16. South Korea
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2022
15.16.2.1. By Treatment Type
15.16.2.2. By End-User
15.17. Australia
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2022
15.17.2.1. By Treatment Type
15.17.2.2. By End-User
15.18. New Zealand
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2022
15.18.2.1. By Treatment Type
15.18.2.2. By End-User
15.19. GCC Countries
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2022
15.19.2.1. By Treatment Type
15.19.2.2. By End-User
15.20. South Africa
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2022
15.20.2.1. By Treatment Type
15.20.2.2. By End-User
15.21. Israel
15.21.1. Pricing Analysis
15.21.2. Market Share Analysis, 2022
15.21.2.1. By Treatment Type
15.21.2.2. By End-User
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Treatment Type
16.3.3. By End-User
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. Otsuka Pharmaceutical
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.2. Sanofi
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.3. Reata Pharmaceuticals
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.4. Galapagos NV
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.5. Janssen Pharmaceuticals
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.6. Regulus Therapeutics
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.7. Xortx Therapeutics
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.8. AceLink Therapeutics, Inc.
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.9. PanoTherapeutics, Inc.
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.10. Exelixis, Inc
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
18. Assumptions & Acronyms Used19. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033
Table 3: Global Market Value (US$ Million) Forecast by End-User, 2018 to 2033
Table 4: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 5: North America Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033
Table 6: North America Market Value (US$ Million) Forecast by End-User, 2018 to 2033
Table 7: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 8: Latin America Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033
Table 9: Latin America Market Value (US$ Million) Forecast by End-User, 2018 to 2033
Table 10: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 11: Europe Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033
Table 12: Europe Market Value (US$ Million) Forecast by End-User, 2018 to 2033
Table 13: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 14: South Asia Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033
Table 15: South Asia Market Value (US$ Million) Forecast by End-User, 2018 to 2033
Table 16: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 17: East Asia Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033
Table 18: East Asia Market Value (US$ Million) Forecast by End-User, 2018 to 2033
Table 19: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 20: Oceania Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033
Table 21: Oceania Market Value (US$ Million) Forecast by End-User, 2018 to 2033
Table 22: MIDDLE EAST AND AFRICA Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 23: MIDDLE EAST AND AFRICA Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033
Table 24: MIDDLE EAST AND AFRICA Market Value (US$ Million) Forecast by End-User, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 1: Global Market Value (US$ Million) by Treatment Type, 2023 to 2033
Figure 2: Global Market Value (US$ Million) by End-User, 2023 to 2033
Figure 3: Global Market Value (US$ Million) by Region, 2023 to 2033
Figure 4: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 7: Global Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033
Figure 8: Global Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033
Figure 9: Global Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033
Figure 10: Global Market Value (US$ Million) Analysis by End-User, 2018 to 2033
Figure 11: Global Market Value Share (%) and BPS Analysis by End-User, 2023 to 2033
Figure 12: Global Market Y-o-Y Growth (%) Projections by End-User, 2023 to 2033
Figure 13: Global Market Attractiveness by Treatment Type, 2023 to 2033
Figure 14: Global Market Attractiveness by End-User, 2023 to 2033
Figure 15: Global Market Attractiveness by Region, 2023 to 2033
Figure 16: North America Market Value (US$ Million) by Treatment Type, 2023 to 2033
Figure 17: North America Market Value (US$ Million) by End-User, 2023 to 2033
Figure 18: North America Market Value (US$ Million) by Country, 2023 to 2033
Figure 19: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 22: North America Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033
Figure 23: North America Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033
Figure 24: North America Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033
Figure 25: North America Market Value (US$ Million) Analysis by End-User, 2018 to 2033
Figure 26: North America Market Value Share (%) and BPS Analysis by End-User, 2023 to 2033
Figure 27: North America Market Y-o-Y Growth (%) Projections by End-User, 2023 to 2033
Figure 28: North America Market Attractiveness by Treatment Type, 2023 to 2033
Figure 29: North America Market Attractiveness by End-User, 2023 to 2033
Figure 30: North America Market Attractiveness by Country, 2023 to 2033
Figure 31: Latin America Market Value (US$ Million) by Treatment Type, 2023 to 2033
Figure 32: Latin America Market Value (US$ Million) by End-User, 2023 to 2033
Figure 33: Latin America Market Value (US$ Million) by Country, 2023 to 2033
Figure 34: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 37: Latin America Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033
Figure 38: Latin America Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033
Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033
Figure 40: Latin America Market Value (US$ Million) Analysis by End-User, 2018 to 2033
Figure 41: Latin America Market Value Share (%) and BPS Analysis by End-User, 2023 to 2033
Figure 42: Latin America Market Y-o-Y Growth (%) Projections by End-User, 2023 to 2033
Figure 43: Latin America Market Attractiveness by Treatment Type, 2023 to 2033
Figure 44: Latin America Market Attractiveness by End-User, 2023 to 2033
Figure 45: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 46: Europe Market Value (US$ Million) by Treatment Type, 2023 to 2033
Figure 47: Europe Market Value (US$ Million) by End-User, 2023 to 2033
Figure 48: Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 49: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 52: Europe Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033
Figure 53: Europe Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033
Figure 54: Europe Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033
Figure 55: Europe Market Value (US$ Million) Analysis by End-User, 2018 to 2033
Figure 56: Europe Market Value Share (%) and BPS Analysis by End-User, 2023 to 2033
Figure 57: Europe Market Y-o-Y Growth (%) Projections by End-User, 2023 to 2033
Figure 58: Europe Market Attractiveness by Treatment Type, 2023 to 2033
Figure 59: Europe Market Attractiveness by End-User, 2023 to 2033
Figure 60: Europe Market Attractiveness by Country, 2023 to 2033
Figure 61: South Asia Market Value (US$ Million) by Treatment Type, 2023 to 2033
Figure 62: South Asia Market Value (US$ Million) by End-User, 2023 to 2033
Figure 63: South Asia Market Value (US$ Million) by Country, 2023 to 2033
Figure 64: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 65: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 66: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 67: South Asia Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033
Figure 68: South Asia Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033
Figure 69: South Asia Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033
Figure 70: South Asia Market Value (US$ Million) Analysis by End-User, 2018 to 2033
Figure 71: South Asia Market Value Share (%) and BPS Analysis by End-User, 2023 to 2033
Figure 72: South Asia Market Y-o-Y Growth (%) Projections by End-User, 2023 to 2033
Figure 73: South Asia Market Attractiveness by Treatment Type, 2023 to 2033
Figure 74: South Asia Market Attractiveness by End-User, 2023 to 2033
Figure 75: South Asia Market Attractiveness by Country, 2023 to 2033
Figure 76: East Asia Market Value (US$ Million) by Treatment Type, 2023 to 2033
Figure 77: East Asia Market Value (US$ Million) by End-User, 2023 to 2033
Figure 78: East Asia Market Value (US$ Million) by Country, 2023 to 2033
Figure 79: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 80: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 81: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 82: East Asia Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033
Figure 83: East Asia Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033
Figure 84: East Asia Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033
Figure 85: East Asia Market Value (US$ Million) Analysis by End-User, 2018 to 2033
Figure 86: East Asia Market Value Share (%) and BPS Analysis by End-User, 2023 to 2033
Figure 87: East Asia Market Y-o-Y Growth (%) Projections by End-User, 2023 to 2033
Figure 88: East Asia Market Attractiveness by Treatment Type, 2023 to 2033
Figure 89: East Asia Market Attractiveness by End-User, 2023 to 2033
Figure 90: East Asia Market Attractiveness by Country, 2023 to 2033
Figure 91: Oceania Market Value (US$ Million) by Treatment Type, 2023 to 2033
Figure 92: Oceania Market Value (US$ Million) by End-User, 2023 to 2033
Figure 93: Oceania Market Value (US$ Million) by Country, 2023 to 2033
Figure 94: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 95: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 96: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 97: Oceania Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033
Figure 98: Oceania Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033
Figure 99: Oceania Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033
Figure 100: Oceania Market Value (US$ Million) Analysis by End-User, 2018 to 2033
Figure 101: Oceania Market Value Share (%) and BPS Analysis by End-User, 2023 to 2033
Figure 102: Oceania Market Y-o-Y Growth (%) Projections by End-User, 2023 to 2033
Figure 103: Oceania Market Attractiveness by Treatment Type, 2023 to 2033
Figure 104: Oceania Market Attractiveness by End-User, 2023 to 2033
Figure 105: Oceania Market Attractiveness by Country, 2023 to 2033
Figure 106: MIDDLE EAST AND AFRICA Market Value (US$ Million) by Treatment Type, 2023 to 2033
Figure 107: MIDDLE EAST AND AFRICA Market Value (US$ Million) by End-User, 2023 to 2033
Figure 108: MIDDLE EAST AND AFRICA Market Value (US$ Million) by Country, 2023 to 2033
Figure 109: MIDDLE EAST AND AFRICA Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 110: MIDDLE EAST AND AFRICA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 111: MIDDLE EAST AND AFRICA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 112: MIDDLE EAST AND AFRICA Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033
Figure 113: MIDDLE EAST AND AFRICA Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033
Figure 114: MIDDLE EAST AND AFRICA Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033
Figure 115: MIDDLE EAST AND AFRICA Market Value (US$ Million) Analysis by End-User, 2018 to 2033
Figure 116: MIDDLE EAST AND AFRICA Market Value Share (%) and BPS Analysis by End-User, 2023 to 2033
Figure 117: MIDDLE EAST AND AFRICA Market Y-o-Y Growth (%) Projections by End-User, 2023 to 2033
Figure 118: MIDDLE EAST AND AFRICA Market Attractiveness by Treatment Type, 2023 to 2033
Figure 119: MIDDLE EAST AND AFRICA Market Attractiveness by End-User, 2023 to 2033
Figure 120: MIDDLE EAST AND AFRICA Market Attractiveness by Country, 2023 to 2033
